Other · developed by Nanobiotix
NBTXR3 is a suspension of inert crystalline hafnium oxide nanoparticles injected into tumors. After radiation is applied, the particles emit electrons, generating free radicals that destroy cancer cells. It is studied in squamous cell carcinoma and non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04892173 | Phase 3 | Carcinoma, Squamous Cell | Recruiting | JNJ |
| NCT07224152 | Phase 1/2 | Locally-Advanced Non-Small Cell Lung Cancer | Recruiting | NBTX |
| NCT06667908 | Phase 2 | Carcinoma, Non-Small-Cell Lung | Recruiting | JNJ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLocally-Advanced Non-Small Cell Lung Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NBTX page.
See NBTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NBTX catalysts and pipeline →